| |
Protocol Number:
03-M-0104
- Title:
PET Imaging of Dopamine D2 Receptors and Extracellular Dopamine with (18F)Fallypride, D-amphetamine, and Alpha-Methyl-Para-Tyrosine in Healthy Subjects
- Number:
03-M-0104
- Summary:
The purpose of this study is to measure molecules on or in cells that interact with a chemical in the nervous system, called dopamine. Investigators will obtain two kinds of images of the brain-a position emission tomography (PET) scan and a magnetic resonance imaging (MRI) scan.
Thirty-eight participants aged 18 to 45 will be enrolled in this study. They must have no history of medical or psychiatric illness, including substance abuse. Participants will have four appointments at NIH. On the first visit, they will undergo a physical exam, a medical history, and lab tests. The second and third visits will involve PET scans and the fourth visit will involve an MRI scan.
Participants will be compensated up to $430 for their involvement in this study.
- Sponsoring Institute:
-
National Institute of Mental Health (NIMH)
- Recruitment Detail
- Type:
Active Accrual Of New Subjects
- Gender:
Male & Female
- Referral Letter Required:
No
- Population Exclusion(s):
Children
- Eligibility Criteria:
INCLUSION CRITERIA:
Age 18-45, inclusive
In good general health on basis of history and physical examination
Normal screening laboratory studies including thyroid function tests, blood count, serum electrolytes, liver and kidney function, and urinalysis
Normal ECG at a resting condition
Normal blood pressure
No illegal drug use based on urine drug screen
EXCLUSION CRITERIA:
Pregnancy/Nursing
Evidence of active mental or neurological illness
Medically significant biochemical or hematological abnormality on screening laboratory studies
Abnormal ECG
High Blood Pressure (above 140 systolic and/or above 90 dystolic pressure)
History of myocardial infarction or angina pectoris
Positive urine drug screen or use of alcohol within one week prior to each PET study
History of substance abuse or dependence within 6 months
Presence of ferromagnetic metal in the body or heart pacemaker
Body weight more than 93 kg to limit AMPT dose to 4g/ day (only for subjects having four PET scans and d-amphetamine and AMPT administration)
Claustrophobia
- Special Instructions:
Currently Not Provided
- Keywords:
-
Thalamus
-
Cerebral Cortices
-
Quantification
-
Reproducibility
-
Dopamine Release
-
(18F) Fallypride
-
D-Amphetamine
-
Alpha-Methyl-Para-Tyrosine (AMPT)
-
PET
-
Dopamine D2 Receptor
- Recruitment Keywords:
-
Healthy Volunteer
-
HV
- Conditions:
-
Healthy
- Investigational Drug(s):
-
(18F)fallypride
- Investigational Device(s):
- None
- Contacts:
-
Patient Recruitment and Public Liaison Office
Building 61
10 Cloister Court
Bethesda, Maryland 20892-4754
Toll Free: 1-800-411-1222
TTY: 301-594-9774 (local),1-866-411-1010 (toll free)
Fax: 301-480-9793
Electronic Mail:prpl@mail.cc.nih.gov
- Citations:
-
Abi-Dargham A, Gil R, Krystal J, Baldwin RM, Seibyl JP, Bowers M, van Dyck CH, Charney DS, Innis RB, Laruelle M. Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort. Am J Psychiatry. 1998 Jun;155(6):761-7. PMID: 9619147
-
Abi-Dargham A, Rodenhiser J, Printz D, Zea-Ponce Y, Gil R, Kegeles LS, Weiss R, Cooper TB, Mann JJ, Van Heertum RL, Gorman JM, Laruelle M. Increased baseline occupancy of D2 receptors by dopamine in schizophrenia. Proc Natl Acad Sci U S A. 2000 Jul 5;97(14):8104-9. PMID: 10884434
-
Anand A, Verhoeff P, Seneca N, Zoghbi SS, Seibyl JP, Charney DS, Innis RB. Brain SPECT imaging of amphetamine-induced dopamine release in euthymic bipolar disorder patients. Am J Psychiatry. 2000 Jul;157(7):1108-14. PMID: 10873919
If you have:
Search The Studies | Help | Questions |
Clinical Center Home | NIH Home
 Warren Grant Magnuson Clinical Center (CC)
National Institutes of Health (NIH)
Bethesda, Maryland 20892. Last update: 10/23/2004
|
|
